Skip to main content
. Author manuscript; available in PMC: 2010 Aug 26.
Published in final edited form as: Diabetes Care. 2004 Jun;27(6):1365–1368. doi: 10.2337/diacare.27.6.1365

Table 1.

Mean change in Si in response to 3 months of troglitazone treatment and corresponding genotype frequencies in women grouped into tertiles of Si change

Change in Si* Pro/Pro Ala/− Total†
Bottom tertile −0.21 ± 0.57 21 (70) 9 (30) 30
Middle tertile 0.91 ± 0.26 25 (78) 7 (22) 32
Top tertile 2.58 ± 1.32 23 (74) 8 (26) 31
Total cohort 1.11 ± 1.41 69 (74) 24 (26) 93

Data are n (%) of women with each genotype or means ± SD. Observed genotype frequencies did not differ significantly from expected frequencies (P = 0.77 by χ2 test).

*

(3-month Si) − (baseline Si); Si is insulin sensitivity calculated with the minimal model (in min−1 per μU/ml · 10−4);

†

the tertiles are of unequal size because the cutoff points are based on all troglitazone-treated subjects (12), including those whose genotyping failed for technical reasons.